Claim 1: an anti CSF-1R antibody, including a heavy chain, characterized in that the variable domain of the heavy chain includes at least one of the following: a CDR with the same sequence as the SEC number. No. 4 of cdr-h1, CDR is the same as the sequence in SEC ID. Number 5 is used for cdr-h2 and a CDR in the same order as SEC ID. No. 6 of CDR-H3. 19. Claim 19: a single DNA sequence that encodes one or more heavy and / or light chains from an antibody in accordance with any one of the 1 to 18 claims. Claim 23: any antibody production process of claims 1 to 18,This includes culturing host cells and screening antibodies in accordance with claim 22. Claim 24: a pharmaceutical ingredient comprising an antibody complying with any one of claims 1 to 18, plus one or more acceptable dissenting, diluent, or drug carrier. Claim 33: antibodies used in accordance with claim 27, 29 or methods used in claim 31, characterized by cancer being selected from groups such as breast cancer, prostate cancer, bone cancer, rectal cancer, leukemia, etc, Lymphoma.Skin cancer, esophageal cancer, gastric cancer, Astro cancer, intrauterine cancer, cervical cancer, bladder cancer, kidney cancer, lung cancer, liver cancer, thyroid cancer, head cancer. And cervical cancer, pancreatic cancer and ovarian cancerReivindicación 1: Un anticuerpo anti-CSF-1R que comprende una cadena pesada, caracterizado porque el dominio variable de la cadena pesada comprende al menos una de las siguientes: una CDR que tiene la secuencia dada en la ID. DE SEC. Nº 4 para CDR-H1, una CDR que tiene la secuencia dada en la ID. DE SEC. Nº 5 para CDR-H2 y una CDR que tiene la secuencia dada en la ID. DE SEC. Nº 6 para CDR-H3. Reivindicación 19: Una secuencia de ADN aislado que codifica una o más cadenas pesadas y/o livianas de un anticuerpo de acuerdo con una cualquiera de las reivindicaciones 1 a 18. Reivindicación 23: Un proceso para la producción del anticuerpo de una cualquiera de las reivindicaciones 1 a 18, que compre
